May Ling Y. serves as the VP, Global Head of Drug Product MSAT at Roche since May 2025. Prior experience includes significant roles at Moderna from November 2020 to April 2025, overseeing operational readiness for GMP facilities and managing international manufacturing operations for the COVID-19 vaccine. Prior to Moderna, May Ling Y. held various positions at Novartis from 2012 to 2020, focusing on product quality management and oversight for biotechnology projects. Other professional experiences include roles at Lonza, Pfizer, Pall Life Sciences, and GSK. May Ling Y. holds a PhD in Chemical Engineering from the University of Bath and completed a Business Awareness Program at Babson College in 2015.
This person is not in the org chart
This person is not in any teams
This person is not in any offices